Tweetovi

Blokirali ste korisnika/cu @mkaeberlein

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mkaeberlein

  1. proslijedio/la je Tweet
    3. velj
    Poništi
  2. prije 15 sati

    I don't know for sure that will help Alzheimer's disease patients, but if someone I loved was diagnosed, I would move move heaven and earth to get them on it as early as possible. It's deeply disappointing that this hasn't been tested yet.

    Poništi
  3. proslijedio/la je Tweet
    23. sij

    Our work was published regarding loss of acidity in the yeast lysosome-like vacuole resulting in age-associated iron sulfur cluster defects. Lots of hard work by many amazing people.

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet
    22. sij

    📹 Innovative peer review is one of the reasons Senior Editor Jess Tyler encourages her colleagues to submit to eLife. Read the for our latest Special Issue on aging research, which Jess is leading alongside Reviewing Editor

    Poništi
  5. proslijedio/la je Tweet
    19. sij

    Have you nominated your pup for the ? is doing his part! A professor is spearheading the effort to improve our understanding of how age:

    Dubs II takes in a football victory.
    Poništi
  6. proslijedio/la je Tweet

    In conclusion: preprint; cite preprints; and don't be a jerk.

    Prikaži ovu nit
    Poništi
  7. 21. sij

    I've learned enough about biological complexity to never claim with certainty what will or won't happen in an experiment. Those who do so demonstrate their own ignorance. My informed guess is that inhibitors will be clinically useful at combatting aging in humans.

    Poništi
  8. 19. sij

    Agreed. And I'd add that the reduction in respiratory infections is perhaps more impactful. I forget the numbers, but I recall the potential if extended to the general population was quite large in terms of elderly deaths and healthcare cost.

    Poništi
  9. 19. sij

    Pan Zheng's group proposed rejuvenation of hematopoietic stem cells in their IMO greatly underappreciated 2009 paper (), although mechanism is unknown. My current guess is that rapa suppresses p16-mediated inflammation (SASP) which impairs immune function.

    Poništi
  10. proslijedio/la je Tweet
    19. sij

    The hypothesis of aging is still alive but our work and others show that we need to find better ways of selectively inhibiting mTORC1, and avoid inhibiting mTORC2 or other kinases that are necessary for health and survival

    Poništi
  11. 19. sij

    Two RCTs with a rapamycin derivative showed significant improvement in immune function in elderly humans. The only RCT that failed was when they left out the rapamycin derivative. Good to maintain healthy skepticism, but don't ignore the data. More rapa RCTs are coming.

    Poništi
  12. proslijedio/la je Tweet
    18. sij
    Odgovor korisniku/ci

    When a rapalog was used, there was a reproducible improvement in humans, and a decrease in immune senescence; the recent failure was with a kinase inhibitor of mTOR, which also inhibits mTORC2 and likely PI3 kinase.

    Poništi
  13. 18. sij

    I suppose, if you want to call up to 60% increase in life expectancy (~2 decades human:mouse equivalent) "a little". Oh, and improved functioning of heart, immune, brain, kidney, intestine, peridontium, ...

    Poništi
  14. 18. sij

    I agree completely. Most of my colleagues are rigorous scientists and would be very cautious about making recommendations that the public should start taking drugs or supplements based on anecdotal, uncontrolled self-experimentation.

    Poništi
  15. 18. sij

    At least a dozen from multiple independent groups. There are many good reviews on this topic from myself, , and among others. You can start with refs 15-28 here:

    Poništi
  16. 18. sij

    Well, as someone who knows at least a little bit about the field, I have to disagree. Pretty sure the "mTOR hypothesis in humans" is alive and well.

    Poništi
  17. 18. sij

    In a perfect world with unlimited resources (not realistic I know), I would use rapamycin alone and perhaps also rapa + RTB101. Would also want to go beyond immune to other indications such as heart and cognitive function, periodontal disease, etc. where rapa may be effective.

    Poništi
  18. 18. sij

    I disagree with your premise. We obviously don't know yet in people, but the data for functional rejuvenation by rapamycin in mice is more extensive, more robust, and (at least so far) more reproducible than for any other intervention.

    Poništi
  19. proslijedio/la je Tweet
    16. sij

    Our paper on senescence-based biomarkers of aging is now published in !! 'A proteomic atlas of senescence-associated secretomes for aging biomarker development' ()

    Poništi
  20. 18. sij

    My thoughts on the unsuccessful PROTECTOR1 trial of RTB101 by resTORbio. As always, discussion and constructive criticisms/comments welcome.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·